KRAS/NRAS/BRAF V600E incidences in the different subpopulations
| Variable . | t(4;14) (n = 575) . | del(17p) (n = 478) . | t(11;14) (n = 1260) . | Whole diagnostic cohort (n = 5934) . | Mut TP53 (n = 344) . | Mut DIS3 (n = 617) . | Mut FAM46C (n = 280) . | AL amyloidosis (n = 489) . | PCL (n = 247) . | Relapses (n = 1429) . | SMM (n = 922) . | MGUS (n = 1168) . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NRAS | 34 (5.9) | 41 (8.6) | 292 (23.2) | 1189 (20) | 26 (7.6) | 137 (22.2) | 21 (7.5) | 27 (5) | 41 (16) | 290 (20) | 80 (8.7) | 32 (2.7) |
| KRAS | 88 (15.3) | 60 (12.6) | 339 (26.9) | 1401 (23.6) | 65 (18.9) | 131 (21.2) | 62 (22) | 43 (9) | 70 (28) | 334 (23) | 136 (14.8) | 65 (5.6) |
| BRAF V600E | 38 (6.6) | 3 (0.6) | 40 (3.2) | 190 (3.2) | 4 (1.2) | 17 (2.8) | 7 (2.5) | 11 (2) | 6 (2.4) | 38 (2.7) | 13 (1.4) | 6 (0.5) |
| Variable . | t(4;14) (n = 575) . | del(17p) (n = 478) . | t(11;14) (n = 1260) . | Whole diagnostic cohort (n = 5934) . | Mut TP53 (n = 344) . | Mut DIS3 (n = 617) . | Mut FAM46C (n = 280) . | AL amyloidosis (n = 489) . | PCL (n = 247) . | Relapses (n = 1429) . | SMM (n = 922) . | MGUS (n = 1168) . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NRAS | 34 (5.9) | 41 (8.6) | 292 (23.2) | 1189 (20) | 26 (7.6) | 137 (22.2) | 21 (7.5) | 27 (5) | 41 (16) | 290 (20) | 80 (8.7) | 32 (2.7) |
| KRAS | 88 (15.3) | 60 (12.6) | 339 (26.9) | 1401 (23.6) | 65 (18.9) | 131 (21.2) | 62 (22) | 43 (9) | 70 (28) | 334 (23) | 136 (14.8) | 65 (5.6) |
| BRAF V600E | 38 (6.6) | 3 (0.6) | 40 (3.2) | 190 (3.2) | 4 (1.2) | 17 (2.8) | 7 (2.5) | 11 (2) | 6 (2.4) | 38 (2.7) | 13 (1.4) | 6 (0.5) |
Data are given as number (percentage).
MGUS, monoclonal gammopathy of undetermined significance; Mut, mutated; SMM, smoldering multiple myeloma.